1. Home
  2. PFX vs LITS Comparison

PFX vs LITS Comparison

Compare PFX & LITS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

PFX

PhenixFIN Corporation

HOLD

Current Price

$44.33

Market Cap

83.5M

Sector

Finance

ML Signal

HOLD

LITS

Lite Strategy Inc.

N/A

Current Price

$1.53

Market Cap

62.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PFX
LITS
Founded
2010
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
83.5M
62.9M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
PFX
LITS
Price
$44.33
$1.53
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
1.1K
466.7K
Earning Date
12-12-2025
11-17-2025
Dividend Yield
3.29%
N/A
EPS Growth
N/A
N/A
EPS
2.06
N/A
Revenue
$25,262,322.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$21.09
N/A
Revenue Growth
13.89
N/A
52 Week Low
$41.00
$1.46
52 Week High
$57.40
$9.00

Technical Indicators

Market Signals
Indicator
PFX
LITS
Relative Strength Index (RSI) 56.01 N/A
Support Level $41.50 N/A
Resistance Level $42.00 N/A
Average True Range (ATR) 0.60 0.00
MACD 0.28 0.00
Stochastic Oscillator 100.00 0.00

Price Performance

Historical Comparison
PFX
LITS

About PFX PhenixFIN Corporation

PhenixFIN Corp is a non-diversified closed end management investment company operating in United States. Its investment objective is to generate current income and capital appreciation by lending directly to privately held middle market companies to expand their business, refinance and make acquisitions. It mainly invests in senior secured first lien term loans, senior secured second lien term loans, unitranche, senior secured first lien notes, subordinated notes and warrants and minority equity securities. It may also invest in securities of foreign companies. Portfolio of the company mainly consists of securities across all sectors. Revenue generated by the company comprises of interest income, dividend and other income earned through investments made.

About LITS Lite Strategy Inc.

Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor and zandelisib, an oral, once-daily, selective PI3K inhibitor. It is a clinical-stage pharmaceutical company committed to the development of novel and differentiated cancer therapies intended to improve outcomes for patients.

Share on Social Networks: